Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NACLC 2022 | HCRN LUN13-175: long term survival of carboplatin, nab-paclitaxel and pembrolizumab in NSCLC

Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, discusses long-term findings from the Phase II HCRN LUN13-175 trial (NCT02382406) of carboplatin, nab-paclitaxel and pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). The progression-free survival (PFS) and overall survival of patients were comparable to that of similarly designed trials such as the CheckMate 9LA (NCT03215706) and KEYNOTE-407 (NCT02775435) studies. Dr Gentzler additionally discusses racially stratified data, with people of color havening similar outcomes to other patients. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Ryan Gentzler, MD, discloses the following commercial interests:

Consultant/Advisory Board: AstraZeneca, Daiichi Sankyo, Sanofi, OncoCyte, Blueprint Medicines, Jazz Pharmaceuticals, Mirati, Pfizer, Gilead

Honorarium: Targeted Oncology, SITC, Rockpointe CME, OncLive, Clinical Care Options

Contracted Support/Research Grant (Institution): Pfizer, Takeda, Jounce Therapeutics, Janssen, BMS, Merck, Daiichi Sankyo, Helsinn, Mirati, RTI International, AstraZeneca, Chugai, Amgen